By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the company to repurchase up to the lesser of $22.75 million worth of its common stock or 650,000 shares, the firm said in a document filed today with the US Securities and Exchange Commission.

In the filing, the Austin, Texas-based firm said that it may repurchase its stock in the open market from time to time or in privately negotiated transactions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.